AU2019301206B2 - Antibody molecules that bind CD137 and OX40 - Google Patents

Antibody molecules that bind CD137 and OX40

Info

Publication number
AU2019301206B2
AU2019301206B2 AU2019301206A AU2019301206A AU2019301206B2 AU 2019301206 B2 AU2019301206 B2 AU 2019301206B2 AU 2019301206 A AU2019301206 A AU 2019301206A AU 2019301206 A AU2019301206 A AU 2019301206A AU 2019301206 B2 AU2019301206 B2 AU 2019301206B2
Authority
AU
Australia
Prior art keywords
antibody molecule
seq
antibody
nos
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019301206A
Other languages
English (en)
Other versions
AU2019301206A1 (en
Inventor
Miguel GASPAR
Michelle Morrow
Edmund POON
Mihriban Tuna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Invox Pharma Ltd
Original Assignee
Invox Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1811407.4A external-priority patent/GB201811407D0/en
Priority claimed from GBGB1818281.6A external-priority patent/GB201818281D0/en
Priority claimed from GBGB1902598.0A external-priority patent/GB201902598D0/en
Application filed by Invox Pharma Ltd filed Critical Invox Pharma Ltd
Publication of AU2019301206A1 publication Critical patent/AU2019301206A1/en
Assigned to F-STAR THERAPEUTICS LIMITED reassignment F-STAR THERAPEUTICS LIMITED Request for Assignment Assignors: F-Star Beta Limited
Assigned to INVOX PHARMA LIMITED reassignment INVOX PHARMA LIMITED Request for Assignment Assignors: F-STAR THERAPEUTICS LIMITED
Application granted granted Critical
Publication of AU2019301206B2 publication Critical patent/AU2019301206B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019301206A 2018-07-12 2019-07-12 Antibody molecules that bind CD137 and OX40 Active AU2019301206B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1811407.4A GB201811407D0 (en) 2018-07-12 2018-07-12 Antibody molecules that bind CD137 and OX40
GB1811407.4 2018-07-12
GBGB1818281.6A GB201818281D0 (en) 2018-11-09 2018-11-09 Antibody molecules that bind CD137 and OX40
GB1818281.6 2018-11-09
GB1902598.0 2019-02-26
GBGB1902598.0A GB201902598D0 (en) 2019-02-26 2019-02-26 Antibody molecules that bind cd137 and ox40
PCT/EP2019/068796 WO2020011966A1 (en) 2018-07-12 2019-07-12 Antibody molecules that bind cd137 and ox40

Publications (2)

Publication Number Publication Date
AU2019301206A1 AU2019301206A1 (en) 2021-03-04
AU2019301206B2 true AU2019301206B2 (en) 2025-10-30

Family

ID=67383740

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019301206A Active AU2019301206B2 (en) 2018-07-12 2019-07-12 Antibody molecules that bind CD137 and OX40

Country Status (15)

Country Link
US (1) US12252537B2 (enExample)
EP (1) EP3820898B1 (enExample)
JP (2) JP7397055B2 (enExample)
KR (1) KR20210031479A (enExample)
CN (1) CN112424229B (enExample)
AU (1) AU2019301206B2 (enExample)
BR (1) BR112021000282A2 (enExample)
CA (1) CA3106048A1 (enExample)
ES (1) ES3044118T3 (enExample)
IL (1) IL280002B2 (enExample)
MX (1) MX2021000399A (enExample)
SG (1) SG11202100172XA (enExample)
TW (1) TWI847989B (enExample)
WO (1) WO2020011966A1 (enExample)
ZA (1) ZA202100718B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11214618B2 (en) 2016-06-20 2022-01-04 F-Star Therapeutics Limited LAG-3 binding members
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
JP7489316B2 (ja) 2017-12-19 2024-05-23 エフ－スター セラピューティクス リミテッド Ｐｄ－ｌｉ抗原結合部位を有するｆｃ結合断片
KR102763158B1 (ko) 2018-04-25 2025-02-04 프로메테우스 바이오사이언시즈, 인크. 최적화된 항tl1a 항체
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
TWI861005B (zh) 2018-07-12 2024-11-11 英商英沃克斯製藥有限公司 結合pd-l1及cd137的抗體分子
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
KR20220103721A (ko) 2019-10-24 2022-07-22 프로메테우스 바이오사이언시즈, 인크. Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도
WO2022178114A1 (en) * 2021-02-17 2022-08-25 Aptevo Research And Development Llc Compositions comprising 4-1bb and ox40 binding proteins and methods of use
AU2022262542A1 (en) 2021-04-22 2023-11-02 Astellas Pharma Inc. Anti-cldn4/anti-cd137 bispecific antibody
CN114478771B (zh) * 2021-12-14 2024-06-25 英诺湖医药(杭州)有限公司 Ox40抗体及其医药用途
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
EP4600651A1 (en) * 2024-02-06 2025-08-13 Consiglio Nazionale Delle Ricerche - CNR Method for diagnosing coeliac disease
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016185016A1 (en) * 2015-05-21 2016-11-24 Alligator Bioscience Ab Novel polypeptides
WO2017077085A2 (en) * 2015-11-04 2017-05-11 Cancer Research Technology Immunomodulatory antibodies

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2245404C3 (de) 1972-09-15 1978-08-31 Robert Bosch Gmbh, 7000 Stuttgart Massewiderstand, insbesondere für Zündkerzen, sowie Verfahren zur Herstellung desselben
JPS531908B2 (enExample) 1973-11-12 1978-01-23
JPS5746634B2 (enExample) 1974-05-10 1982-10-04
JPS5146628A (ja) 1974-10-17 1976-04-21 Nippon Denso Co Teikoirisupaakupuragu
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
CA2318576C (en) 1997-12-01 2009-04-14 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Antibodies, including fv molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
DE19818214A1 (de) 1998-04-24 1999-10-28 Bosch Gmbh Robert Zündkerze für eine Brennkraftmaschine
MXPA01011950A (es) 1999-05-27 2002-05-06 Gov Health & Human Serv Inmunoconjugados que tienen alta afinidad de enlace.
JP4578025B2 (ja) 2001-07-06 2010-11-10 日本特殊陶業株式会社 スパークプラグ
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
ATE414718T1 (de) 2005-01-05 2008-12-15 F Star Biotech Forsch & Entw Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
WO2006088447A1 (en) 2005-02-15 2006-08-24 Gtc Biotherapeutics, Inc. An anti-cd137 antibody as an agent in the treatement of cancer and glycosylation variants thereof
ES2429340T3 (es) 2005-03-10 2013-11-14 Morphotek, Inc. Anticuerpos anti-mesotelina
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
HUE066143T2 (hu) 2007-06-26 2024-07-28 F Star Therapeutics Ltd Kötõágensek megjelenítése
PL2215121T3 (pl) 2007-11-26 2016-07-29 Bayer Ip Gmbh Przeciwciała przeciwko mezotelinie i ich zastosowania
EP2242771B1 (en) 2007-12-14 2013-07-17 Bristol-Myers Squibb Company Binding molecules to the human ox40 receptor
RS51975B (sr) 2008-04-11 2012-02-29 Emergent Product Development Seattle Llc. Cd37 imunoterapeutski proizvod i njegova kombinacija sa bifunkcionalnim hemoterapeutskim sredstvom
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP2358390A1 (en) 2008-11-13 2011-08-24 Emergent Product Development Seattle, LLC Cd37 immunotherapeutic combination therapies and uses thereof
US8217149B2 (en) 2008-12-09 2012-07-10 Genentech, Inc. Anti-PD-L1 antibodies, compositions and articles of manufacture
US8460660B2 (en) 2009-03-24 2013-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-mesothelin antibodies
AR076284A1 (es) 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
LT3279215T (lt) 2009-11-24 2020-04-10 Medimmune Limited Tiksliniai surišantys agentai prieš b7-h1
EP2407487A1 (en) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
CA2810359C (en) 2010-09-09 2021-06-22 Pfizer Inc. 4-1bb binding molecules
TWI477513B (zh) 2010-12-20 2015-03-21 建南德克公司 抗間皮素（ｍｅｓｏｔｈｅｌｉｎ）抗體及免疫接合物
SI2691417T2 (sl) 2011-03-29 2025-05-30 Roche Glycart Ag FC variante protitelesa
EP2546268A1 (en) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalising immunoglobulin
LT2785375T (lt) 2011-11-28 2020-11-10 Merck Patent Gmbh Anti-pd-l1 antikūnai ir jų panaudojimas
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
US20140004121A1 (en) 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
JP5276742B1 (ja) 2012-08-09 2013-08-28 日本特殊陶業株式会社 点火プラグ
WO2014052064A1 (en) 2012-09-27 2014-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin antibodies and methods for eliciting potent antitumor activity
SMT201900242T1 (it) 2012-12-03 2019-05-10 Bristol Myers Squibb Co Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici
SI2970464T1 (sl) 2013-03-15 2020-08-31 Glaxosmithkline Intellectual Propety Development Limited Anti-LAG-3 vezavni proteini
EP2970484B2 (en) 2013-03-15 2022-09-21 Amgen Inc. Heterodimeric bispecific antibodies
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
GB201317622D0 (en) 2013-10-04 2013-11-20 Star Biotechnology Ltd F Cancer biomarkers and uses thereof
US10899840B2 (en) 2014-02-04 2021-01-26 Pfizer Inc. Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
CA2936962C (en) 2014-03-14 2024-03-05 Novartis Ag Antibody molecules to lag-3 and uses thereof
WO2015198312A1 (en) 2014-06-24 2015-12-30 Ccam Therapeutics Ltd. Compositions comprising antibodies to ceacam-1 and lag-3 for cancer therapy
JP5902757B2 (ja) 2014-06-24 2016-04-13 日本特殊陶業株式会社 スパークプラグ
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
JP6665160B2 (ja) 2014-08-10 2020-03-13 フェデラル−モーグル・イグニション・リミテッド・ライアビリティ・カンパニーＦｅｄｅｒａｌ−Ｍｏｇｕｌ Ｉｇｎｉｔｉｏｎ Ｌｌｃ 改良されたシールを有するスパークプラグ
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
CA2960824A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
TW201619200A (zh) 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
GB201500319D0 (en) 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
US10259881B2 (en) 2015-02-22 2019-04-16 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD137
TW201642897A (zh) 2015-04-08 2016-12-16 Ｆ 星生物科技有限公司 Ｈｅｒ２結合劑治療
AU2016258977C1 (en) 2015-05-04 2022-07-14 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
JP6025921B1 (ja) 2015-06-22 2016-11-16 日本特殊陶業株式会社 スパークプラグ
AU2016293101B2 (en) 2015-07-15 2022-06-16 Pieris Pharmaceuticals Gmbh Novel proteins specific for LAG-3
CA2993177A1 (en) 2015-07-22 2017-01-26 Sorrento Therapeutics, Inc. Antibody therapeutics that bind lag3
SI3328419T1 (sl) 2015-07-30 2021-11-30 Macrogenics, Inc. PD-1-vezavne molekule in postopki uporabe le-teh
CA2994631A1 (en) 2015-08-07 2017-02-16 Pieris Pharmaceuticals Gmbh Novel fusion polypeptide specific for lag-3 and pd-1
CN108026169B (zh) 2015-09-22 2021-05-28 苏州丁孚靶点生物技术有限公司 抗人cd137的完全人抗体及其应用
KR101782487B1 (ko) 2015-09-24 2017-09-27 재단법인 목암생명과학연구소 신규 항-메소텔린 항체 및 이를 포함하는 조성물
KR20180053674A (ko) 2015-10-02 2018-05-23 에프. 호프만-라 로슈 아게 공자극 tnf 수용체에 특이적인 이중특이성 항체
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
CA3132021C (en) 2015-11-18 2024-03-12 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
WO2017087901A2 (en) 2015-11-19 2017-05-26 Sutro Biopharma, Inc. Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
SG10201912405TA (en) 2016-01-11 2020-02-27 Inhibrx Inc Multivalent and multispecific 41bb-binding fusion proteins
CN108602371B (zh) 2016-03-18 2020-03-24 大日本印刷株式会社 中间转印介质、中间转印介质与热转印片的组合、以及印刷物的形成方法
AU2017252233A1 (en) 2016-04-22 2018-11-15 Alligator Bioscience Ab Novel bispecific polypeptides against CD137
AR108377A1 (es) 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
CA3025345A1 (en) 2016-05-27 2017-11-30 Abbvie Biotherapeutics Inc. Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
US20190106494A1 (en) 2016-06-13 2019-04-11 Askgene Pharma Inc. PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US11214618B2 (en) 2016-06-20 2022-01-04 F-Star Therapeutics Limited LAG-3 binding members
CN109563171B (zh) 2016-06-20 2023-09-19 F-星治疗有限公司 结合pd-l1和lag-3的结合分子
CN107523546A (zh) 2016-06-20 2017-12-29 上海细胞治疗研究院 一种高效稳定表达抗体的nk细胞及其用途
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
US11746152B2 (en) 2016-07-20 2023-09-05 Stcube, Inc. Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated PD-L1
EP4342912A3 (en) 2016-09-23 2024-05-22 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
GB201616699D0 (en) 2016-09-30 2016-11-16 Mab Designs Ltd Antibodies
GB201619648D0 (en) 2016-11-21 2017-01-04 Alligator Bioscience Ab Novel antibodies and uses thereof
WO2018115859A1 (en) 2016-12-20 2018-06-28 Kymab Limited Multispecific antibody with combination therapy for immuno-oncology
GB201700345D0 (en) 2017-01-09 2017-02-22 F-Star Beta Ltd Conditional agonists of immune responses
EP3630167A1 (en) 2017-05-26 2020-04-08 NovImmune SA Anti-cd47 x anti-mesothelin antibodies and methods of use thereof
EP3630842A2 (en) 2017-05-30 2020-04-08 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
AU2018309339C1 (en) 2017-08-04 2025-08-21 BioNTech SE Binding agents binding to PD-L1 and CD137 and use thereof
EP3470426A1 (en) 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
JP7489316B2 (ja) 2017-12-19 2024-05-23 エフ－スター セラピューティクス リミテッド Ｐｄ－ｌｉ抗原結合部位を有するｆｃ結合断片
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
TWI861005B (zh) 2018-07-12 2024-11-11 英商英沃克斯製藥有限公司 結合pd-l1及cd137的抗體分子
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
WO2020229626A1 (en) 2019-05-14 2020-11-19 F-Star Delta Limited Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016185016A1 (en) * 2015-05-21 2016-11-24 Alligator Bioscience Ab Novel polypeptides
WO2017077085A2 (en) * 2015-11-04 2017-05-11 Cancer Research Technology Immunomodulatory antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
H. Z. QUI ET AL: THE JOURNAL OF IMMUNOLOGY, vol. 187, no. 7, 31 August 2011 (2011-08-31), US, pages 3555 - 3564, XP055356944, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1101244 *
WOZNIAK-KNOPP GBARTL SBAUER AMOSTAGEER MWOISETSCHLAGER MANTES BETTL KKAINER MWEBERHOFER GWIEDERKUM S: PROTEIN ENG. DES. SEL., vol. 23, no. 4, 2010, pages 289 - 97, XP009137665, DOI: doi:10.1093/protein/gzq005 *

Also Published As

Publication number Publication date
TW202019963A (zh) 2020-06-01
BR112021000282A2 (pt) 2021-04-06
JP7701964B2 (ja) 2025-07-02
US20220048996A1 (en) 2022-02-17
IL280002B2 (en) 2025-05-01
CA3106048A1 (en) 2020-01-16
JP2021524267A (ja) 2021-09-13
TWI847989B (zh) 2024-07-11
WO2020011966A1 (en) 2020-01-16
EP3820898B1 (en) 2025-09-03
IL280002B1 (en) 2025-01-01
ES3044118T3 (en) 2025-11-26
JP2024019415A (ja) 2024-02-09
CN112424229A (zh) 2021-02-26
IL280002A (en) 2021-03-01
CN112424229B (zh) 2024-07-30
US12252537B2 (en) 2025-03-18
JP7397055B2 (ja) 2023-12-12
AU2019301206A1 (en) 2021-03-04
EP3820898A1 (en) 2021-05-19
SG11202100172XA (en) 2021-02-25
KR20210031479A (ko) 2021-03-19
MX2021000399A (es) 2021-05-27
ZA202100718B (en) 2025-07-30

Similar Documents

Publication Publication Date Title
AU2019301206B2 (en) Antibody molecules that bind CD137 and OX40
JP7587656B2 (ja) Ｐｄ－ｌ１及びｃｄ１３７に結合する抗体分子
AU2019303080B2 (en) Fc binding fragments comprising an OX40 antigen-binding site
US20210309753A1 (en) Mesothelin and cd137 binding molecules
RU2817602C2 (ru) Молекулы антител, которые связывают cd137 и ox40
RU2826084C2 (ru) МОЛЕКУЛЫ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТ PD-L1 и CD137
HK40122804A (en) Antibody molecules that bind pd-l1 and cd137
HK40050345A (en) Antibody molecules that bind pd-l1 and cd137
HK40050345B (en) Antibody molecules that bind pd-l1 and cd137

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: F-STAR THERAPEUTICS LIMITED

Free format text: FORMER APPLICANT(S): F-STAR BETA LIMITED

PC1 Assignment before grant (sect. 113)

Owner name: INVOX PHARMA LIMITED

Free format text: FORMER APPLICANT(S): F-STAR THERAPEUTICS LIMITED